Tenax Therapeutics (NASDAQ:TENX) Receives New Coverage from Analysts at Guggenheim

Guggenheim assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report issued on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $16.00 target price on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on the company. William Blair initiated coverage on Tenax Therapeutics in a research note on Monday, September 30th. They set an outperform rating for the company. StockNews.com initiated coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a sell rating for the company.

Tenax Therapeutics Stock Up 12.4 %

NASDAQ:TENX opened at $3.79 on Monday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $61.20. The stock has a 50 day moving average price of $3.76 and a 200 day moving average price of $3.57.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, equities analysts forecast that Tenax Therapeutics will post -6.75 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.